Table 1.

List of anticancer therapies targeting sphingolipid metabolism in ovarian cancer

Name	Target/activity	Stage of development	References
Ceramide analogs
C6-ceramide nanoliposomes	Survivin, prosurvival protein kinase Cζ-dependent AKT and ERK signaling cascades, and VEGF production	Phase I	[78,81–83,94]
Inhibitors of S1P metabolism
FTY720	S1PR1	FDA-approved for multiple sclerosis	[29,106,137]
Anti-S1P (Sphingomab)	S1P	Phase II	[43,95,96]
(Sonepcizumab)
ABC294640	SPHK2, GCS, DES	Phase Ib and II	[122,129]
SKI-II	SPHK1, SPHK2	Preclinical	[54,138]
Tamoxifen	GCS, AC, P-gp	FDA-approved	[30]
Safingol	SPHK, PKC	Phase I	[118,139,140]